Month: June 2021

Posted on

Sophi.io ของ The Globe and Mail คว้ารางวัล Digiday Media Award

Digiday มอบรางวัล Best Publisher Platform ให้กับ Sophi.io ชุดเครื่องมือระบบอัตโนมัติ เพิ่มประสิทธิภาพ และการคาดการณ์ที่ขับเคลื่อนด้วยปัญญาประดิษฐ์ที่พัฒนาโดย The Globe and Mail

โตรอนโต, June 30, 2021 (GLOBE NEWSWIRE) — Sophi.io ระบบอัตโนมัติและการคาดการณ์ที่ใช้ปัญญาประดิษฐ์ของ The Globe and Mail ได้รับรางวัล Digiday Media Award 2021 สำหรับ Best Publisher Platform ซึ่งเป็นรางวัลที่ยอมรับเทคโนโลยีที่ประสบความสำเร็จมากที่สุดในการช่วยให้ผู้เผยแพร่บรรลุเป้าหมาย

“AI เป็นเทคโนโลยีที่จำเป็นสำหรับการช่วยให้ผู้เผยแพร่เพิ่มมูลค่าที่แท้จริงให้กับเนื้อหา ซึ่งจะช่วยให้มาตรวัดความสำเร็จเป็นมากกว่าจำนวนการรับชมเพจและความนิยม ตัวอย่างเช่น Sophi สามารถให้ข้อมูลว่าแต่ละบทความใน The Globe and Mail มีส่วนช่วยในการรักษาสมาชิก การเข้าซื้อ แนวโน้มในการสมัครสมาชิก และค่าโฆษณามากเพียงใด นอกจากนี้ เพื่อใช้งานการเรียนรู้ของเครื่องอย่างมีประสิทธิภาพ ปัจจุบันพนักงานประมาณ 10% ของ The Globe and Mail เป็นนักวิทยาศาสตร์และวิศวกรข้อมูล ซึ่งได้รับการว่าจ้างให้พัฒนา Sophi และพัฒนากลยุทธ์ให้ดียิ่งขึ้นไปอีก” Digiday กล่าว

รางวัลนี้เป็นเกียรติแก่บริษัท เทคโนโลยี และแคมเปญที่โดดเด่นครอบคลุมด้านสื่อในปีที่ผ่านมา “ในปีนี้ การแข่งขันดุเดือดมากและโปรแกรมก็แข็งแกร่ง นวัตกรรมและแนวคิดที่ยิ่งใหญ่ได้ขยายขอบเขตการแข่งขันสำหรับผู้ชนะหลายราย แม้จะเป็นปีที่การกักตัวได้ตีกรอบการทำงานและการเล่นของผู้คนก็ตาม” Digiday กล่าว

Phillip Crawley ผู้เผยแพร่และ CEO ของ The Globe and Mail ได้ให้ความเห็นว่า: “รู้สึกเป็นเกียรติที่ได้รับเลือกให้เป็นผู้ชนะรางวัล Media Award ของ Digiday สำหรับ Best Publisher Platform เรามักจะไม่ได้มีปฏิสัมพันธ์กับบริษัทต่างๆ ทั้งในด้านอุตสาหกรรมสื่อและการตลาด แต่การลงทุนของเราใน Sophi นั้นได้รับแรงผลักดันจากความเข้าใจว่าเทคโนโลยีของเราสามารถขับเคลื่อนประสิทธิภาพและการเติบโตทางเศรษฐกิจได้โดยตรงสำหรับบริษัทต่างๆ ในหลากหลายอุตสาหกรรม”

ผู้เข้ารอบสุดท้ายรายอื่นๆ ในหมวดหมู่ Best Publisher Platform ได้แก่ Piano, Connatix, Insticator, Duration Media และ Adapex LLC

Sophi เป็นระบบปัญญาประดิษฐ์ที่ช่วยให้ผู้เผยแพร่ระบุและใช้ประโยชน์จากเนื้อหาที่มีค่าที่สุดของตนได้ ซึ่งจะมีความสามารถในการคาดการณ์ที่มีประสิทธิภาพ โดยใช้การประมวลผลภาษาธรรมชาติ Sophi Dynamic Paywall เป็น Paywall ระบบอัตโนมัติบนไซต์แบบไดนามิกเรียลไทม์เต็มรูปแบบที่ปรับแต่งได้ตามต้องการที่วิเคราะห์ทั้งเนื้อหาและพฤติกรรมของผู้ใช้เพื่อกำหนดว่าเวลาใดที่จะเก็บเงินจากผู้อ่านหรือสอบถามอีเมลแอดเดรส และเวลาใดที่ไม่ควรทำ

Sophi Site Automation จัดการเนื้อหาดิจิทัลโดยอัตโนมัติเพื่อค้นหาและโปรโมทบทความที่มีค่าที่สุด โดยจะวางเนื้อหา 99% ไว้ในหน้าดิจิทัลทั้งหมดของ The Globe and Mail รวมถึงหน้าหลักและหน้าส่วนต่างๆ Sophi ประสบความสำเร็จอย่างมากจนปัจจุบันถูกนำมาใช้สำหรับการจัดรูปแบบการพิมพ์ด้วย Sophi พร้อมให้บริการแก่ผู้เผยแพร่ทั่วโลกเพื่อให้ผู้ผลิตเนื้อหาของตนมุ่งเน้นที่การสร้างเนื้อหาที่ดีที่สุดเท่าที่จะเป็นไปได้

เมื่อต้นเดือนนี้ Sophi ได้รับรางวัล 2021 International News Media Association (INMA) Global Media Awards สาขา Best in Show ในอเมริกาเหนือ และ Best Use of Data to Automate or Personalize Sophi ยังได้รับรางวัล Online Journalism Award (OJA) สำหรับนวัตกรรมทางเทคนิคในการให้บริการวารสารศาสตร์ดิจิทัล ซึ่งมอบให้โดย Online News Association (ONA) และรางวัล World Digital Media Award และ North American Digital Media Award ที่มอบให้โดย The World Association of News Publishers (WAN-IFRA) ในประเภท Best Digital News Start-up

เกี่ยวกับ Sophi.io

Sophi.io (https://www.sophi.io) เป็นชุดเครื่องมือเพิ่มประสิทธิภาพและการคาดการณ์ที่ขับเคลื่อนด้วย AI ซึ่งช่วยให้ผู้เผยแพร่เนื้อหาตัดสินใจเชิงกลยุทธ์และยุทธวิธีที่สำคัญ โซลูชันของ Sophi มีให้บริการตั้งแต่ Sophi Site Automation และ Sophi for Paywalls ไปจนถึง Sophi Analytics ซึ่งเป็นระบบสนับสนุนการตัดสินใจสำหรับผู้เผยแพร่เนื้อหา Sophi ถูกออกแบบมาเพื่อปรับปรุงเมตริกที่มีความสำคัญต่อธุรกิจมากที่สุด เช่น การรักษาผู้สมัครสมาชิกและการเข้าซื้อกิจการ การมีส่วนร่วม ความใหม่ ความถี่และปริมาณ

ติดต่อ
Jamie Rubenovitch
หัวหน้าฝ่ายการตลาด, Sophi.io
The Globe and Mail
416-585-3355
jrubenovitch@globeandmail.com
Posted on

Laos’ Covid-19 infections reach 2,121

The nationwide number of Covid-19 infections, cumulated since March 2020, has reached 2,121 including 1,981 recoveries and three deaths.

The National Taskforce Committee for Covid-19 Prevention and Control told a press conference in Vientiane on Jun 30 that 20 new cases have been recorded over the past 24 hours including 16 imported cases and four local transmissions.

The imported cases included nine in Savannakhet, six in Champassak, and one in Khammuan.

All of the new local transmissions were recorded in Vientiane province.

As of Jun 28, 2021 over 1.46 million people across the country had been vaccinated against Covid-19 with over 916,000 given first doses and more than 544,000 given second doses.

Source: Lao News Agency

Posted on

WHO Certifies China Malaria-Free

GENEVA – The World Health Organization has certified China, the most populous country in the world, as malaria-free.

It has taken China seven decades to reach this milestone. The country has gone from 30 million cases of malaria in the 1940s to zero cases today.

Director of the World Health Organization’s Global Malaria Program Pedro Alonso tells VOA the achievement should act as an inspiration to other malaria endemic countries around the world.

“China, that at one point had 30 million cases of malaria every year and I would place that country among the top two burdened countries in the world can actually drive down malaria and get rid of this scourge of mankind,” Alonso said.

China is the first country in the WHO Western Pacific Region to be awarded a malaria-free certification in more than three decades. Other countries in the region that have achieved that status include Australia, Singapore, and Brunei.

Globally, 40 countries and territories have been declared malaria-free. The most recent include El Salvador, Algeria, Argentina, Paraguay, and Uzbekistan.

Eliminating malaria is a long, complex process involving many factors. Alonso says economic development, improvement in peoples’ living conditions and the implementation of measures aimed at preventing, controlling, and treating malaria are critical for success.

“Vector control mostly through insecticide-treated bed nets will for the years to come remain the backbone of our prevention efforts. Artemisinin combination therapies will remain the backbone of our treatment efforts,” Alonso said.

The WHO estimates there are still 229 million new cases of malaria annually, leading to more than 400,000 deaths. Africa is home to 94 percent of those cases and deaths.

Alonso says the mosquito in Africa is very effective in the transmission of malaria. This he says is one of the many reasons why it is particularly challenging to rid the continent of the disease.

“And of course, all of this is compounded by lack of economic and social development, difficulties in communication, poverty, housing, lack of electricity. So, it is a compounded effect. It is where China was 60 years ago…and, we are having a lot of difficulty, even to maintain the gains achieved over the last 20 years,” Alonso said.

While substantial progress in the prevention and control of malaria is possible with today’s available tools, Alonso says only a highly effective vaccine can eradicate the disease.

The WHO malaria chief says he is cautiously optimistic that such a vaccine is on the horizon. He notes a pilot project to develop the world’s first malaria vaccine, RTS,S, in three countries in sub-Saharan Africa, has been shown to provide partial protection against malaria in young children.

He says the vaccine, which was introduced in 2019, is likely not to be the hoped-for game changer everyone seeks. But he adds it is a very good start.

Source: Voice of America

Posted on

Sinovac Vaccine Falls Short of Expectations, But Options Limited

“Better than nothing.”

That’s one infectious disease expert’s assessment of Sinovac Biotech’s COVID-19 vaccine, following reports that hundreds of Indonesian health care workers who had received the vaccine caught the disease anyway.

At least 10 doctors have died despite having been fully vaccinated with two doses of Sinovac’s CoronaVac vaccine, according to the Indonesian Medical Association.

It’s unclear how widespread these “breakthrough” infections are. It’s also not clear how severe most of the infections are. Little peer-reviewed data on the vaccine are available.

What information is available suggests that the vaccine is less potent than others, especially against the highly contagious delta variant that was first detected in India.

However, access to more effective vaccines is limited in much of the world, experts note. Indonesia is one of dozens of countries where the Chinese company’s vaccine makes up a substantial part of the available doses.

While the shortage of published peer-reviewed data makes it hard to evaluate the vaccine, a few available studies provide a glimpse.

The government of Uruguay released data earlier this month showing CoronaVac reduced COVID-19 infections by 61%, hospitalizations by 92% and deaths by 95%.

Although not peer-reviewed, the study is one of a few that compare CoronaVac with another vaccine.

Pfizer-BioNTech

The Pfizer-BioNTech shot performed better against infections in general in the study, lowering rates by 78%. But hospitalizations and deaths were about the same.

It’s not clear what the dominant variant was during the study, however.

A key measure of vaccine potency is the level of neutralizing antibodies — the proteins the immune system produces that prevent the virus from infecting cells.

The Pfizer and Moderna vaccines produce very high levels of these antibodies, which help maintain protection against variants, said Peter Hotez, dean of the National School of Tropical Medicine and a professor at the Baylor College of Medicine.

“Yes, you’re getting some breakthrough infections with the delta variant, but they tend not to be serious infections,” he said. “People aren’t being hospitalized or losing their lives because of COVID-19.”

“When you look at some of the data on the Sinovac vaccine,” he added, “the levels of virus-neutralizing antibody, even after two doses, can still be quite low.”

The Sinovac vaccine produced lower levels of these antibodies than seven other vaccines, including those from Pfizer, Moderna, University of Oxford-AstraZeneca and Johnson & Johnson, according to a study in the journal Nature Medicine.

The antibody response is even less effective against the delta variant, which has exploded in Indonesia and many parts of the world.

It’s not clear, however, exactly what that decline means for patients. The vaccine still offers protection against the most serious forms of the disease, a Chinese official told state media.

In China’s first delta outbreak, in Guangdong province earlier this month, “none of those vaccinated infections became severe cases, and none of the severe cases were vaccinated,” said Feng Zijian, former deputy director at the Chinese Center for Disease Control and Prevention.

Meanwhile, supplies of other vaccines are arriving slowly in much of the world.

“Sometimes, that’s all people have access to,” Hotez said. “It’s better than nothing.”

Source: Voice of America

Posted on

Zoom to Acquire Kites GmbH

Kites Team to Help Enhance Zoom’s Machine Translation Capabilities

SAN JOSE, Calif. and KARLSRUHE, Germany, June 29, 2021 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM) today announced it has signed a definitive agreement to acquire Karlsruhe Information Technology Solutions – Kites GmbH (“Kites”), a start-up dedicated to developing real-time Machine Translation (“MT”) solutions. The terms of the transaction were not disclosed.

Kites was founded in 2015 and has academic roots with Karlsruhe Institute of Technology, where co-founders Dr. Alex Waibel and Dr. Sebastian Stüker are faculty members. Kites’ talented team of 12 research scientists will help Zoom’s engineering team advance the field of MT to improve meeting productivity and efficiency by providing multi-language translation capabilities for Zoom users.

“We are continuously looking for new ways to deliver happiness to our users and improve meeting productivity, and MT solutions will be key in enhancing our platform for Zoom customers across the globe,” said Velchamy Sankarlingam, President of Product and Engineering at Zoom. “With our aligned missions to make collaboration frictionless – regardless of language, geographic location, or other barriers – we are confident Kites’ impressive team will fit right in with Zoom.”

“Kites emerged with the mission of breaking down language barriers and making seamless cross-language interaction a reality of everyday life, and we have long admired Zoom for its ability to easily connect people across the world,” said Dr. Waibel and Dr. Stüker. “We know Zoom is the best partner for Kites to help advance our mission and we are excited to see what comes next under Zoom’s incredible innovation engine.”

Dr. Stüker and the rest of the Kites team will remain based in Karlsruhe, Germany, where Zoom looks forward to investing in growing the team. Zoom is exploring opening an R&D center in Germany in the future. Dr. Waibel will become a Zoom Research Fellow, a role in which he will advise on Zoom’s MT research and development.

Forward-Looking Statements
This press release contains express and implied “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 related to Zoom’s acquisition of Kites that involves substantial risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements in this communication include, among other things, statements about the potential benefits of the transaction, our development of our MT solutions, our ability to integrate the Kites team, and potential growth opportunities. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “project,” “will,” “would,” “should,” “could,” “can,” “predict,” “potential,” “target,” “explore,” “continue,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. However, not all forward-looking statements contain these identifying words. By their nature, these statements are subject to numerous uncertainties and risks, including factors beyond our control, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. These assumptions, uncertainties and risks include that, among others, the possibility that the anticipated benefits of the transaction are not realized when expected or at all, division of management’s attention from ongoing business operations and opportunities, potential adverse reactions or changes to business or employee relationships, the ability to integrate Kites successfully, and other factors that may affect future results of Zoom. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption “Risk Factors” and elsewhere in our most recent filings with the Securities and Exchange Commission (the “SEC”), including our quarterly report on Form 10-Q for the quarter ended April 30, 2021. Forward-looking statements speak only as of the date the statements are made and are based on information available to Zoom at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. Zoom assumes no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, except as required by law.

About Zoom
Zoom is for you. We help you express ideas, connect to others, and build toward a future limited only by your imagination. Our frictionless communications platform is the only one that started with video as its foundation, and we have set the standard for innovation ever since. That is why we are an intuitive, scalable, and secure choice for individuals, small businesses, and large enterprises alike. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Visit zoom.com and follow @zoom.

About Kites
Karlsruhe Information Technology Solutions – Kites GmbH is a start-up company founded in 2015 by Dr. Sebastian Stüker and Dr. Alex Waibel with the express purpose of transforming the latest research in speech translation technology into viable products. Kites’ mission is breaking down language barriers and making seamless cross-language interaction a reality of everyday life. Kites aims to provide custom services to its customers in order to provide technology and services that fit and are operated and maintained at the necessary quality levels.

Zoom Press Relations
Colleen Rodriguez
Global Media Relations Lead
press@zoom.us

Zoom Investor Relations
Tom McCallum
Head of Investor Relations
investors@zoom.us

Posted on

Nikkiso Clean Energy & Industrial Gases Group Announces Formation of Nikkiso Clean Energy & Industrial Gases (SEA) Sdn. Bhd in Malaysia

TEMECULA, Calif., June 29, 2021 (GLOBE NEWSWIRE) — Nikkiso Clean Energy & Industrial Gases Group (Group), a subsidiary of Nikkiso Co., Ltd (Japan), is proud to announce the creation of Nikkiso Clean Energy & Industrial Gases (SEA) Sdn. Bhd. effective 1st July 2021. This company represents the combining of our two Malaysia business units: Cryogenic Industries and Cryoquip in a new joint facility.

This merger represents another step forward in the Group’s overall corporate growth strategy, emphasizing their ability to provide both global and regional support for sales and service. The name change emphasizes the support and strength of the larger Group; Clean Energy is the growth engine and Industrial Gases the core foundation.

The new, larger facility provides a strong support structure for future growth. Ideally placed within the region to support their key customers and provide an additional focus on clean energy, the 56,400 square foot facility is twice the size of their previous center. It has an improved capacity for loading flow and manufacturing for vaporizers, vacuum lines, process skid fabrication and assembly, refurbishment work, as well as pumps parts and service. In addition, it offers opportunities for sharing resources with other Nikkiso group companies (supporting Nikkiso Cryo or for fabrication of LEWA SEA and/or Geveke Malaysia skids).

According to Tim Born, the Vice President of Nikkiso CE&IG for South East Asia and Oceania;

“This new facility will provide a one-stop shop for the Nikkiso CE&IG Group’s cryogenic process equipment, installations and services. The amalgamation of our two businesses in Malaysia and the willingness to expand our facility and capabilities highlights our Group’s commitment to this region. Our new facility will provide timely local support for our complete range of products and services, and I look forward to working together with our customers and our talented local Nikkiso CE&IG team to provide the products and services this growing region needs.”

Nikkiso CE&IG (SEA) is responsible for business in South East Asia, namely Malaysia, Singapore, Thailand, Indonesia, Philippines, Myanmar, Vietnam, Brunei, Laos and Cambodia, as well as Taiwan, Bangladesh and Pakistan, and provides support to the Middle East, India, Africa and Australia.

Contact Information:

Nikkiso Clean Energy and Industrial Gases (SEA) Sdn. Bhd. 199601016333
(formerly known as Cryoquip Sdn. Bhd. 388684-P)
Lot 862, Jalan Subang 8, Taman Perindustrian Subang
47600 Subang, Selangor, Malaysia

Tel: +60 3 8081 8330
Fax: +60 3 8081 8360
Email: sales.sea@nikkisoceig.com Website: www.nikkisoCEIG.com

ABOUT CRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (now a member of Nikkiso Co., Ltd.) member companies manufacture engineered cryogenic gas processing equipment and small-scale process plants for the liquefied natural gas (LNG), well services and industrial gas industries. Founded over 50 years ago, Cryogenic Industries is the parent company of ACD, Cosmodyne and Cryoquip and a commonly-controlled group of approximately 20 operating entities.

For more information, please visit www.nikkisoCEIG.com and www.nikkiso.com.

MEDIA CONTACT:
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com